COMMUNIQUÉS West-GlobeNewswire

Emblem launches new line of Oil Capsules
10/12/2018
Capsules are latest addition to the Company’s growing line of innovative medical cannabis products TORONTO, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”), through [...]
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress
10/12/2018
CAMBRIDGE, Mass., and BEIJING, China, Dec. 10, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative [...]
Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
10/12/2018
NEW HAVEN, Conn., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors [...]
OraSure Technologies Announces 2019 Annual Meeting Date
10/12/2018
BETHLEHEM, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) today announced that its 2019 Annual Meeting of Stockholders is scheduled to be held at 10:00 a.m. EDT (7:00 a.m. PDT) on [...]
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019
10/12/2018
Orphazyme A/S Company announcement No. 14/2018 Company Registration No. 32266355 Copenhagen, December 10, 2018 – Orphazyme A/S, a biopharmaceutical company dedicated to developing treatments for patients living with [...]
German Clinic Orders Second Acarix CADScor®System to Further Boost Patient Capacity
10/12/2018
Press release Malmö, Sweden 10 th of December 2018 German Clinic Orders Second Acarix CADScor ® System to Further Boost Patient Capacity After three months of strong results using Acarix's CADScor®System to evaluate [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 5, 2018
10/12/2018
Disclosure of Share Capital and Voting Rights Outstanding as of December 5, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 5 décembre 2018
10/12/2018
Nombre total de droits de vote et d'actions composant le capital social au 5 décembre 2018 (Conformément à l'article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l'AMF) [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2018
10/12/2018
Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2018 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité [...]
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2018
10/12/2018
Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2018 (Conformément à l'article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l'AMF) [...]
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
10/12/2018
Mereo BioPharma Group plc ("Mereo" or the "Company" or the "Group") LONDON, Dec. 10, 2018 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare [...]
Bio-on and Hera create Lux-on the new challenge to produce bioplastic from CO2.
10/12/2018
Newco Lux-on created by Bio-on, alongside Gruppo Hera, to develop a revolutionary technology to produce biopolymers from CO2 (carbon dioxide). Following 2 years of research by Bio-on scientists working in Italy and USA [...]
Bio-on et Hera insufflent la vie à Lux-on Toute dernière initiative pour produire des bioplastiques à base de CO2.
10/12/2018
On annonce la fondation de la société Lux-on, par Bio-on, avec la participation du groupe Hera, dont la mission est la mise au point d’une technologie révolutionnaire pour la production de bio-polymères à partir de CO 2 [...]
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
10/12/2018
Basel, Switzerland, December 10, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba ® (isavuconazole) by Astellas Pharma Inc. ("Astellas") in the United States [...]
Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
08/12/2018
Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy alone; consistent with [...]
Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
08/12/2018
ARV-471 Degraded Estrogen Receptor and Provided Improved Anti-Tumor Activity When Compared to SOC, Both as a Monotherapy and in Combination NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN [...]
Segra Postpones Go Public Strategy Citing Cannabis Market Conditions
08/12/2018
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ VANCOUVER, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Segra International Corp., a cannabis agritech company, [...]
Abattis Announces Acquisition of Fertilizer Company NutriVida
08/12/2018
VANCOUVER, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp. (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to announce that it has signed a non-binding letter of intent [...]
Emerald Health Therapeutics Closes $10.8 Million Prospectus Sale
08/12/2018
VICTORIA, British Columbia, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH; OTCQX:EMHTF) ("Emerald" or the “Company”) closed today its prospectus sale (the “Offering”) to a single Canadian [...]

Pages